Business Context and Reporting Period
Company: ARVINAS, INC. (ARVN)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: Arvinas is a biotechnology company developing targeted protein degradation therapies using its PROTAC platform. The company has one FDA-approved product, VEPPANU (vepdegestrant), for advanced breast cancer, which is being prepared for commercialization via a third-party partner selected jointly with Pfizer. The company maintains a pipeline of clinical candidates including ARV-102 (neurology), ARV-806 (oncology), ARV-393 (oncology), and ARV-027 (neuromuscular).
Key Financial Metrics
| Metric (in millions) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $15.6 | $188.8 |
| Net (Loss) Income | $(57.6) | $82.9 |
| Operating Expenses | $79.4 | $117.4 |
| Research & Development (R&D) | $60.3 | $90.8 |
| General & Administrative (G&A) | $19.1 | $26.6 |
| Cash, Cash Equivalents & Marketable Securities | $614.9 | $685.4 |
| Net Cash Used in Operating Activities | $(69.2) | $(88.9) |
| Long-Term Debt | $0.3 | $0.4 |
Note: Revenue is derived primarily from collaboration agreements (Pfizer, Novartis, Genentech) and asset sales, recognized ratably over performance periods. The company has not generated revenue from product sales.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by $173.2 million (92%) compared to Q1 2025. This was primarily driven by a $175.6 million decrease in revenue from the Pfizer Vepdegestrant collaboration due to accounting estimate changes in 2025 related to the removal of two Phase 3 trials from the development plan.
- Net Loss vs. Net Income: The company reported a net loss of $57.6 million in Q1 2026, compared to net income of $82.9 million in Q1 2025. The prior year income was significantly boosted by the aforementioned revenue recognition adjustments.
- Expense Reduction: Total operating expenses decreased by $38.0 million. R&D expenses dropped $30.5 million, driven by reduced personnel costs ($15.6 million) and external expenses ($14.2 million), reflecting workforce reductions and cost optimization initiatives.
- Liquidity: Cash and marketable securities decreased by approximately $70.5 million quarter-over-quarter, primarily due to operating cash outflows and net purchases of marketable securities.
Guidance, Outlook, and Risks
- Commercialization of VEPPANU: Following FDA approval in Q2 2026, Arvinas and Pfizer are on track to select a third-party partner for commercialization. Arvinas expects to receive a $50.0 million milestone payment upon approval, offset by payments to Yale University. The company does not expect to generate product sales revenue until after a third-party partner is selected.
- Cash Runway: Management believes current cash, cash equivalents, and marketable securities ($614.9 million) are sufficient to fund operations into the second half of 2028.
- Pipeline Progress:
- ARV-102: Phase 1b trial in PSP is on clinical hold pending toxicology data; expected to begin in H2 2026.
- ARV-806: Dose escalation in Phase 1 completed; dose expansion cohort to begin.
- ARV-393: Early responses observed in Phase 1; combination cohort with glofitamab initiated.
- ARV-027: Phase 1 trial in healthy volunteers initiated.
- Restructuring: The company is completing a 15% workforce reduction announced in September 2025, expected to finish by Q2 2026. Q1 2026 included $1.1 million in restructuring charges.
- Risks: Key risks include the failure to secure a commercialization partner for VEPPANU on favorable terms, delays in clinical trials, and the need for additional financing if capital resources are exhausted sooner than expected.
Investor Verification Checklist
- Commercialization Partner: Verify the timeline and terms for the selection of the third-party commercialization partner for VEPPANU, as this is critical for future revenue realization.
- Milestone Payment Timing: Confirm the receipt and net amount of the $50.0 million FDA approval milestone payment after Yale University offsets.
- Cash Burn Rate: Monitor quarterly cash usage to validate the "second half of 2028" runway estimate, especially given the lack of near-term product sales revenue.
- Clinical Trial Status: Track the resolution of the clinical hold on the ARV-102 Phase 1b trial and the initiation of the dose expansion for ARV-806.
- Revenue Recognition: Review future quarters for any further adjustments to collaboration revenue estimates, as seen in the significant variance between Q1 2025 and Q1 2026.